Quantitative Cervical Spinal Cord 3T Proton MR Spectroscopy in Multiple Sclerosis

References

1. 1.↵
   1. He J,
   2. Inglese M,
   3. Li BS,
   4. et al

   . Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging—initial experience. Radiology 2005; 234: 211–17

   PubMedWeb of Science
2. 2.↵
   1. Cucurella MG,
   2. Rovira A,
   3. Río J,
   4. et al

   . Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed 2000; 13: 57–63

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Sijens PE,
   2. Mostert JP,
   3. Oudkerk M,
   4. et al

   . 1H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006; 16: 489–95

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Adalsteinsson E,
   2. Langer-Gould A,
   3. Homer RJ,
   4. et al

   . Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003; 24: 1941–45

   Abstract/FREE Full Text
5. 5.↵
   1. Narayanan PA,
   2. Doyle TJ,
   3. Lai D,
   4. et al

   . Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56–71

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Nelson F,
   2. Poonawalla AH,
   3. Hou P,
   4. et al

   . Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007; 28: 1645–49

   Abstract/FREE Full Text
7. 7.↵
   1. Chard DT,
   2. Griffin CM,
   3. McLean MA,
   4. et al

   . Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 2342–52

   Abstract/FREE Full Text
8. 8.↵
   1. Bozzali M,
   2. Cercignani M,
   3. Sormani MP,
   4. et al

   . Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 2002; 23: 985–88

   Abstract/FREE Full Text
9. 9.↵
   1. Dehmeshki J,
   2. Chard DT,
   3. Leary SM,
   4. et al

   . The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003; 250: 67–74

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Kapeller P,
    2. McLean MA,
    3. Griffin CM,
    4. et al

    . Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001; 248: 131–38

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Narayanan PA

    . Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15: 46S 57S

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Miki Y,
    2. Grossman RI,
    3. Udupa JK,
    4. et al

    . Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images—lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 1999; 213: 395–99

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Zivadinov R,
    2. Leist TP

    . Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005; 15: 10S–21S

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Brex PA,
    2. Ciccarelli O,
    3. O'Riordan JI,
    4. et al

    . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–64

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Barkhof F

    . The clinico-pathological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239–45

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Wolinsky JS,
    2. Narayana PA,
    3. Fenstermacher MJ

    . Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40: 1764–69

    Abstract/FREE Full Text
17. 17.↵
    1. Inglese M,
    2. Li BS,
    3. Rusinek H,
    4. et al

    . Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003; 50: 190–95

    CrossRefPubMedWeb of Science
18. 18.↵
    1. De Stefano N,
    2. Narayanan S,
    3. Francis GS,
    4. et al

    . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65–70

    CrossRefPubMedWeb of Science
19. 19.↵
    1. De Stefano N,
    2. Matthews PM,
    3. Fu L,
    4. et al

    . Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469–77

    Abstract/FREE Full Text
20. 20.↵
    1. Kapeller P,
    2. Brex PA,
    3. Chard D,
    4. et al

    . Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002; 8: 207–10

    Abstract/FREE Full Text
21. 21.↵
    1. Kendi AT,
    2. Tan FU,
    3. Kendi M,
    4. et al

    . MR spectroscopy of cervical spinal cord in patients with multiple sclerosis. Neuroradiology 2004; 46: 764–69

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Blamire AM,
    2. Cader S,
    3. Lee M,
    4. et al

    . Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy. Magn Reson Med 2007; 58: 880–85

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Henning A,
    2. Schär M,
    3. Kollias SS,
    4. et al

    . Quantitative magnetic resonance spectroscopy in the entire human cervical spinal cord and beyond at 3T. Magn Reson Med 2008; 59: 1250–58

    CrossRefPubMed
24. 24.↵
    1. Cooke F,
    2. Blamire AM,
    3. Korlpara LP,
    4. et al

    . Proton spectroscopy of the motor pathway in patients with spinocerebellar ataxia (SCA). In: Proceedings of the 13th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Miami Beach, FL. May 7–13, 2005: 1227
25. 25.↵
    1. Dydak U,
    2. Kollias SS,
    3. Schär M,
    4. et al

    . MR spectroscopy in different regions of the spinal cord and in spinal cord tumors. In: Proceedings of the 13th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Miami Beach, FL. May 7–13, 2005: 813
26. 26.↵
    1. Ciccarelli O,
    2. Wheeler-Kingshott CA,
    3. McLean MA,
    4. et al

    . Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 2007; 130: 2220–31

    Abstract/FREE Full Text
27. 27.↵
    1. Marliani AF,
    2. Clementi V,
    3. Albini-Riccioli L,
    4. et al

    . Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med 2007; 57: 160–63

    CrossRefPubMedWeb of Science
28. 28.↵
    1. McDonald WI,
    2. Compston A,
    3. Edan G,
    4. et al

    . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–27

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Tran TK,
    2. Vigneron DB,
    3. Sailasuta N,
    4. et al

    . Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000; 43: 23–33

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Cooke FJ,
    2. Blamire AM,
    3. Manners DN,
    4. et al

    . Quantitative proton magnetic resonance spectroscopy of the cervical spinal cord. Magn Reson Med 2004; 51: 1122–28

    CrossRefPubMed
31. 31.↵
    1. Provencher SW.

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672–79

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Gomez-Anson B,
    2. MacManus DG,
    3. Parker GJM,
    4. et al

    . In vivo 1H-magnetic resonance spectroscopy of the spinal cord in humans. Neuroradiology 2000; 42: 515–17

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Dubey P,
    2. Smith M,
    3. Bonekamp D,
    4. et al

    . Proton MR spectroscopic imaging of the human cervical spine at 3 Tesla. In: Proceedings of the 13th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Miami Beach, FL. May 7–13, 2005: 812
34. 34.↵
    1. Edden RA,
    2. Bonekamp D,
    3. Smith MA,
    4. et al

    . Proton MR spectroscopic imaging of the medulla and cervical spinal cord. J Magn Reson Imaging 2007; 26: 1101–05

    CrossRefPubMed
35. 35.↵
    1. Bot JC,
    2. Barkhof F.

    . Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 2009; 19: 81–99

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Thorpe JW,
    2. Kidd D,
    3. Moseley IF,
    4. et al

    . Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46: 373–78

    Abstract/FREE Full Text
37. 37.↵
    1. Kidd D,
    2. Thorpe JW,
    3. Kendall BE,
    4. et al

    . MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 15–19

    Abstract/FREE Full Text
38. 38.↵
    1. Bot JC,
    2. Barkhof F,
    3. Polman CH,
    4. et al

    . Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62: 226–33

    Abstract/FREE Full Text
39. 39.↵
    1. Bjartmar C,
    2. Kidd G,
    3. Mork S,
    4. et al

    . Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893–901

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Ruiz-Pena JL,
    2. Pinero P,
    3. Sellers G,
    4. et al

    . Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol 2004; 4: 8

    CrossRefPubMed
41. 41.↵
    1. Bot JC,
    2. Blezer EL,
    3. Kamphorst W,
    4. et al

    . The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology 2004; 233: 531–40

    PubMedWeb of Science
42. 42.↵
    1. Bergers E,
    2. Bot JC,
    3. De Groot CJ,
    4. et al

    . Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002; 59: 1766–71

    Abstract/FREE Full Text
43. 43.↵
    1. Rashid W,
    2. Davies GR,
    3. Chard DT,
    4. et al

    . Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 2006; 77: 51–55

    Abstract/FREE Full Text
44. 44.↵
    1. Nijeholt G,
    2. van Walderveen MA,
    3. Castelijns JA,
    4. et al

    . Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998; 121: 687–97

    Abstract/FREE Full Text
45. 45.↵
    1. Stevenson VL,
    2. Leary SM,
    3. Losseff NA,
    4. et al

    . Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998; 51: 234–38

    Abstract/FREE Full Text
46. 46.↵
    1. Riccioli LA,
    2. Marliani AF,
    3. Clementi V,
    4. et al

    . Evolutive study of relapsing-remitting multiple sclerosis with cervical proton magnetic resonance spectroscopy: a case report. Neuroradiol J 2008; 21: 511–17